GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guangzhou Wondfo Biotech Co Ltd (SZSE:300482) » Definitions » Debt-to-EBITDA

Guangzhou Wondfo Biotech Co (SZSE:300482) Debt-to-EBITDA : 0.60 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Guangzhou Wondfo Biotech Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Guangzhou Wondfo Biotech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥21 Mil. Guangzhou Wondfo Biotech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥597 Mil. Guangzhou Wondfo Biotech Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥1,035 Mil. Guangzhou Wondfo Biotech Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.60.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Guangzhou Wondfo Biotech Co's Debt-to-EBITDA or its related term are showing as below:

SZSE:300482' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02   Med: 0.32   Max: 1.05
Current: 1.05

During the past 13 years, the highest Debt-to-EBITDA Ratio of Guangzhou Wondfo Biotech Co was 1.05. The lowest was 0.02. And the median was 0.32.

SZSE:300482's Debt-to-EBITDA is ranked better than
54.92% of 437 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs SZSE:300482: 1.05

Guangzhou Wondfo Biotech Co Debt-to-EBITDA Historical Data

The historical data trend for Guangzhou Wondfo Biotech Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangzhou Wondfo Biotech Co Debt-to-EBITDA Chart

Guangzhou Wondfo Biotech Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.69 0.64 0.46 0.71

Guangzhou Wondfo Biotech Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.93 1.88 1.67 0.60

Competitive Comparison of Guangzhou Wondfo Biotech Co's Debt-to-EBITDA

For the Medical Devices subindustry, Guangzhou Wondfo Biotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangzhou Wondfo Biotech Co's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guangzhou Wondfo Biotech Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Guangzhou Wondfo Biotech Co's Debt-to-EBITDA falls into.



Guangzhou Wondfo Biotech Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Guangzhou Wondfo Biotech Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.01 + 580.529) / 847.81
=0.71

Guangzhou Wondfo Biotech Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(20.779 + 596.743) / 1034.992
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Guangzhou Wondfo Biotech Co  (SZSE:300482) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Guangzhou Wondfo Biotech Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Guangzhou Wondfo Biotech Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Guangzhou Wondfo Biotech Co (SZSE:300482) Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Lizhishan Road, Science City, Luogang District, Guangdong, Guangzhou, CHN, 510641
Guangzhou Wondfo Biotech Co Ltd manufactures medical diagnostic tests. Its products include immunodiagnostic rapid test kits, including fertility, which include pregnancy HCG, ovulation LH, and others. The company's products are used in a clinical test, field test, and personal health management, among others.
Executives
He Xiao Wei Director
Kang Ke Ren Executives
Yu Fang Xia Executives
Li Wen Mei Directors, executives
Wang Ji Hua Director
Peng Zhong Xiong Executives
Zhao Ya Ping Executives
Luo Hong Supervisors
Zhou Yong Supervisors

Guangzhou Wondfo Biotech Co (SZSE:300482) Headlines

No Headlines